EV71 vaccine containing adjuvant combination

A technology of EV71 and EV71-VLP, applied in the field of biomedicine, can solve problems such as weak immunogenicity and poor immune response, and achieve the effect of reducing morbidity, severe disease and death cases
CN108853488AInactive Publication Date: 2018-11-23SOUTH CHINA UNITED VACCINE INST
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SOUTH CHINA UNITED VACCINE INST
Publication Date
2018-11-23
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an EV71 vaccine containing an adjuvant combination. The EV71 vaccine is prepared from the following main components: EV71 virus-like particles (EV71-VLPs), an aluminum adjuvantand polyinosinic acid cytidylic acid (poly I: C). The immunogenicity of the EV71 protein vaccine provided by the invention is superior to that of monophosphate lipids A (MPLA), Al or a poly I: C adjuvant vaccine which is singly used currently; the EV71 vaccine not only can well induce humoral immune response with antigen specificity, but also can induce high-level cellular immune response; the vaccine can effectively prevent related diseases caused by EV71 virus infection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biomedicine, and in particular relates to an EV71 vaccine containing an adjuvant combination. Background technique

[0002] According to the reported molecular epidemiological studies on EV71, enterovirus 71 (EV71) is the main cause of severe and fatal HFMD, which can cause 80% severe disease and 93% mortality. Due to the lack of effective specific drugs for the treatment of hand, foot and mouth disease, vaccination has become the most important means of preventing and controlling the outbreak and widespread epidemic of this kind of disease. Vaccines developed around HFMD mainly include whole virus inactivated vaccines, EV71-VLP vaccines, vector vaccines and VP1 recombinant protein vaccines, etc. Among them, whole virus inactivated vaccines are the fastest-growing and fastest-growing. The whole virus vaccine is put into use.

[0003] Virus-like particles (VLPs) are empty shell structures that do not contain viral...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More